Hasil Pencarian - Federica Caggia

  • Menampilkan 1 - 4 hasil dari 4
Perbaiki Hasil
  1. 1
    Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges

    Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges oleh Krisida Cerma, Federico Piacentini, Luca Moscetti, Monica Barbolini, Fabio Canino, Antonio Tornincasa, Federica Caggia, Sara Cerri, Alessia Molinaro, Massimo Dominici, Claudia Omarini

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis

    T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis oleh Claudia Omarini, Federico Piacentini, Isabella Sperduti, Krisida Cerma, Monica Barbolini, Fabio Canino, Cecilia Nasso, Christel Isca, Federica Caggia, Massimo Dominici, Luca Moscetti

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy

    Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy oleh Angela Toss, Angela Toss, Marta Venturelli, Monica Civallero, Claudia Piombino, Federica Domati, Guido Ficarra, Francesca Combi, Francesca Combi, Eleonora Cabitza, Federica Caggia, Elena Barbieri, Monica Barbolini, Luca Moscetti, Claudia Omarini, Federico Piacentini, Federico Piacentini, Giovanni Tazzioli, Giovanni Tazzioli, Massimo Dominici, Massimo Dominici, Laura Cortesi

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study

    Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study oleh Fabio Canino, Monica Barbolini, Ugo De Giorgi, Tommaso Fontana, Valeria Gaspari, Caterina Gianni, Lorenzo Gianni, Antonio Maestri, Santino Minichillo, Luca Moscetti, Antonella Mura, Stefania Vittoria Luisa Nicoletti, Claudia Omarini, Rachele Pagani, Samanta Sarti, Angela Toss, Claudio Zamagni, Riccardo Cuoghi Costantini, Federica Caggia, Giuseppina Antonelli, Federica Baglio, Lorenzo Belluzzi, Giulio Martinelli, Salvatore Natalizio, Ornella Ponzoni, Massimo Dominici, Federico Piacentini

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: